Zobrazeno 1 - 10
of 40
pro vyhledávání: '"S H, Ferris"'
Publikováno v:
Neurology. 72:1555-1561
Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind
Autor:
J C, Morris, M R, Farlow, S H, Ferris, A F, Kurz, A, Maelicke, L, Rasmusen, D, Wilkinson, B, Yan
Publikováno v:
Clinical therapeutics. 23
Autor:
S H, Ferris
Publikováno v:
Alzheimer disease and associated disorders. 13
Clinical trials of antidementia drugs must use a performance-based cognitive assessment as a primary outcome measure. There are well-established criteria for selecting or developing an optimal cognitive battery for Alzheimer disease (AD) trials that
Autor:
G W, Small, P V, Rabins, P P, Barry, N S, Buckholtz, S T, DeKosky, S H, Ferris, S I, Finkel, L P, Gwyther, Z S, Khachaturian, B D, Lebowitz, T D, McRae, J C, Morris, F, Oakley, L S, Schneider, J E, Streim, T, Sunderland, L A, Teri, L E, Tune
Publikováno v:
JAMA. 278(16)
A consensus conference on the diagnosis and treatment of Alzheimer disease (AD) and related disorders was organized by the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society on January 4 an
Autor:
S H, Ferris, J A, Mackell
Publikováno v:
Alzheimer disease and associated disorders. 11
The use of behavioral scales is an important component in determining efficacy of new drugs in clinical trials for Alzheimer disease (AD). Behavioral assessment in clinical trials must be sensitive to disease heterogeneity, disease progression, and d
Autor:
E, Koss, M, Weiner, C, Ernesto, J, Cohen-Mansfield, S H, Ferris, M, Grundman, K, Schafer, M, Sano, L J, Thal, R, Thomas, P J, Whitehouse
Publikováno v:
Alzheimer disease and associated disorders. 11
As part of the effort of the NIA Alzheimer's disease cooperative study to develop improved instruments for quantifying effects in Alzheimer's disease (AD) clinical trials, patterns of agitated behaviors were evaluated with the Cohen-Mansfield Agitati
Autor:
L S, Schneider, J T, Olin, R S, Doody, C M, Clark, J C, Morris, B, Reisberg, F A, Schmitt, M, Grundman, R G, Thomas, S H, Ferris
Publikováno v:
Alzheimer disease and associated disorders. 11
This article reports the development and psychometric properties of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). At present, a number of unvalidated CGIC scales are used in clinical trials, with various
Autor:
F A, Schmitt, W, Ashford, C, Ernesto, J, Saxton, L S, Schneider, C M, Clark, S H, Ferris, J A, Mackell, K, Schafer, L J, Thal
Publikováno v:
Alzheimer disease and associated disorders. 11
Measurement of cognitive dysfunction in the early stages of Alzheimer's disease (AD) has been well studied and there are many objective tests in use for this purpose. However, with the exception of clinical rating scales, such as the Clinical Dementi
Autor:
M, Sano, J A, Mackell, M, Ponton, P, Ferreira, J, Wilson, S, Pawluczyk, E, Pfeiffer, R G, Thomas, S, Jin, K, Schafer, M, Schittini, M, Grundman, S H, Ferris, L J, Thal
Publikováno v:
Alzheimer disease and associated disorders. 11
Development of improved outcome measures for Alzheimer's disease (AD) clinical trials is a major objective of the Alzheimer's Disease Cooperative Study (ADCS), an NIA-sponsored, multisite clinical trials consortium. The ADCS is committed to recruitin
Autor:
S H, Ferris, J A, Mackell, R, Mohs, L S, Schneider, D, Galasko, P J, Whitehouse, F A, Schmitt, M, Sano, R G, Thomas, C, Ernesto, M, Grundman, K, Schafer, L J, Thal
Publikováno v:
Alzheimer disease and associated disorders. 11
Evaluating treatment efficacy in Alzheimer's disease (AD) clinical trials requires optimal assessment methods to determine the extent and clinical meaningfulness of potential therapeutic effects of pharmacologic agents. Development of improved outcom